<DOC>
	<DOCNO>NCT00596479</DOCNO>
	<brief_summary>The purpose study human stable coronary artery disease ( CAD ) treatable PCI ( percutaneous coronary intervention ) evaluate safety efficacy subcutaneous delivery recombinant granulocyte colony stimulate factor rG-CSF ( Filgrastim , Neupogen® , Amgen Switzerland ) regard promotion collateral growth .</brief_summary>
	<brief_title>Filgrastim Promotion Collateral Growth Patients With CAD</brief_title>
	<detailed_description>The purpose study human stable coronary artery disease ( CAD ) treatable PCI ( percutaneous coronary intervention ) evaluate safety efficacy subcutaneous delivery recombinant granulocyte colony stimulate factor rG-CSF ( Filgrastim , Neupogen® , Amgen Switzerland ) regard promotion collateral growth .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Age &gt; 18 year old 1 3vessel coronary artery disease ( CAD ) Stable angina pectoris At least 1 stenotic lesion suitable PCI No Qwave myocardial infarction area undergo CFI measurement Written inform consent participate study Patients admit emergency Acute myocardial infarction Unstable CAD CAD treat best CABG Patients overt neoplastic disease Patients diabetic retinopathy Liver kidney disease Premenopausal woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>CAD</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Collaterals</keyword>
	<keyword>CFI</keyword>
	<keyword>perfusion</keyword>
</DOC>